Skip to content

Monocyte Profiles in Critically Ill Patients With Pseudomonas Aeruginosa Sepsis

Phenotypical Und Functional Characterization of Macrophages in Critically Ill Patients With Pseudomonas Aeruginosa Induced Sepsis

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03044223
Acronym
MIPSA
Enrollment
100
Registered
2017-02-06
Start date
2014-08-31
Completion date
2026-12-31
Last updated
2024-01-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Critically Ill, Pseudomonal Bacteraemia, Pseudomonas Gastrointestinal Tract Infection, Pseudomonas Infections, Pseudomonas; Pneumonia, Pseudomonas Septicemia, Pseudomonas Urinary Tract Infection, Sepsis, Sepsis, Severe

Keywords

pseudomonas aeruginosa, critically ill patient, sepsis, monocyte, macrophage, cytokine, severity of disease

Brief summary

The present study focuses on patients with Pseudomonas aeruginosa (PSA) sepsis. The aim of the present study is to find out whether the M1 (pro-inflammatory) or M2 (anti-inflammatory) phenotype predominates in blood monocytes in critically ill patients with PSA-sepsis, and whether the severity of sepsis and outcome is associated with distinct monocyte phenotype and function.

Detailed description

During bacterial related sepsis, one of the key playing cells are macrophages, monocytes and T-lymphocytes (Hotchkiss et al., 2003). Macrophages and monocytes are supposed to be essential for the septic reaction to Gram-negative bacteria (Hotchkiss et al. 2003). Generally, there are two dominant types of macrophages: the pro-inflammatory M1 macrophage and the anti-inflammatory M2 macrophage (Mantovani et al., 2006). Similar to this macrophage characteristics, monocytes can also be categorized into pro-or anti-inflammatory. These macrophage/monocyte phenotypes can be differentiated in vitro from freshly isolated human blood monocytes using either GM-CSF giving raise to M1 macrophage/monocyte or M-CSF resulting in M2 macrophage/monocyte (Mantovani et al., 2006; Neu et al., 2013). Brunialti et al. (2012) have already demonstrated that the population of antiinflammatory M2 monocytes in septic patients is bigger than the pro-inflammatory M1 population. However, the authors did not further analyze the underlying mechanisms of M2 polarization nor did they identify the sepsis-causing pathogens. In the present study, monocytes and macrophages of patients with Pseudomonas aeruginosa (PSA) sepsis are characterized by their surface marker expression profile via flow cytometry and cytokine pattern by ELISA in vivo and after ex-vivo LPS stimulation. In addition, an ex-vivo model system for PSA induced sepsis is validated. Blood of critically ill patients in the ICU infected with PSA is sampled to isolate peripheral blood mononuclear cells (PBMCs). Blood monocytes are analyzed for surface marker expression to determine the relative proportions of M1 and M2 monocytes in these patients and in healthy controls by flow cytometry

Interventions

None listed

Sponsors

University of Ulm
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
Yes

Inclusion criteria

* age \> 18 years * critically ill patients with sepsis * microbiologically proven infection with Pseudomonas aeruginosa

Exclusion criteria

* life expectancy \< 24 hours * participation in other studies

Design outcomes

Primary

MeasureTime frameDescription
Monocyte surface marker expression in critically ill patients with Pseudomonas aeruginosa sepsistwo yearsMonocyte type 1, type 2 surface marker expression

Secondary

MeasureTime frameDescription
Cytokine concentrations in serum and production after ex-vivo stimulation of isolated monocytes of critically ill patients with Pseudomonas aeruginosa sepsis with LPSfour yearsIL-8 and IFN-gamma

Countries

Germany

Contacts

Primary ContactManfred Weiss, MD, MBA
manfred.weiss@uniklinik-ulm.de+49 731 500 60226
Backup ContactEberhard Barth, MD
eberhard.barth@uniklinik-ulm.de+49 731 500 60050

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026